Cargando…

Meeting report: the 2021 FSHD International Research Congress

Facioscapulohumeral muscular dystrophy (FSHD) is the second most common genetic myopathy, characterized by slowly progressing and highly heterogeneous muscle wasting with a typical onset in the late teens/early adulthood [1]. Although the etiology of the disease for both FSHD type 1 and type 2 has b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jagannathan, Sujatha, de Greef, Jessica C., Hayward, Lawrence J., Yokomori, Kyoko, Gabellini, Davide, Mul, Karlien, Sacconi, Sabrina, Arjomand, Jamshid, Kinoshita, June, Harper, Scott Q.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762812/ https://www.ncbi.nlm.nih.gov/pubmed/35039091 http://dx.doi.org/10.1186/s13395-022-00287-8

Ejemplares similares

Meeting report: the 2020 FSHD International Research Congress
por: Kyba, Michael, et al.
Publicado: (2020)

The facioscapulohumeral muscular dystrophy Rasch‐built overall disability scale (FSHD‐RODS)
por: Mul, Karlien, et al.
Publicado: (2021)

FSHD: copy number variations on the theme of muscular dystrophy
por: Cabianca, Daphne Selvaggia, et al.
Publicado: (2010)

DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2021)

Direct interplay between two candidate genes in FSHD muscular dystrophy
por: Ferri, Giulia, et al.
Publicado: (2015)

MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy
por: Runfola, Valeria, et al.
Publicado: (2023)

DNA Methylation Analysis of the Macrosatellite Repeat Associated with FSHD Muscular Dystrophy at Single Nucleotide Level
por: Huichalaf, Claudia, et al.
Publicado: (2014)

Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nuclei
por: Jiang, Shan, et al.
Publicado: (2020)

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study
por: LoRusso, Samantha, et al.
Publicado: (2019)

A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics
por: Campbell, Amy E., et al.
Publicado: (2023)

Polycomb repressive complex 1 provides a molecular explanation for repeat copy number dependency in FSHD muscular dystrophy
por: Casa, Valentina, et al.
Publicado: (2017)

FSHD / OPMD / MYOTONIC DYSTROPHY: P.229 Open-Label study of losmapimod evaluating safety, tolerability, and changes in biomarker and clinical outcome assessments in subjects with FSHD1
por: Mellion, M., et al.
Publicado: (2020)

A Long ncRNA Links Copy Number Variation to a Polycomb/Trithorax Epigenetic Switch in FSHD Muscular Dystrophy
por: Cabianca, Daphne S., et al.
Publicado: (2012)

Designed U7 snRNAs inhibit DUX4 expression and improve FSHD-associated outcomes in DUX4 overexpressing cells and FSHD patient myotubes
por: Rashnonejad, Afrooz, et al.
Publicado: (2020)

WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2023)

Rbfox1 Downregulation and Altered Calpain 3 Splicing by FRG1 in a Mouse Model of Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Pistoni, Mariaelena, et al.
Publicado: (2013)

Genotype-phenotype correlations in FSHD
por: Zernov, Nikolay, et al.
Publicado: (2019)

Current Therapeutic Approaches in FSHD
por: Wang, Leo H., et al.
Publicado: (2021)

Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD)
por: Goselink, Rianne J. M., et al.
Publicado: (2016)

Specific Loss of Histone H3 Lysine 9 Trimethylation and HP1γ/Cohesin Binding at D4Z4 Repeats Is Associated with Facioscapulohumeral Dystrophy (FSHD)
por: Zeng, Weihua, et al.
Publicado: (2009)

Does DNA Methylation Matter in FSHD?
por: Salsi, Valentina, et al.
Publicado: (2020)

Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
por: Lu-Nguyen, Ngoc, et al.
Publicado: (2021)

Precise Epigenetic Analysis Using Targeted Bisulfite Genomic Sequencing Distinguishes FSHD1, FSHD2, and Healthy Subjects
por: Gould, Taylor, et al.
Publicado: (2021)

From the ESMO Congress 2021
por: Sidaway, Peter
Publicado: (2021)

Gene expression during normal and FSHD myogenesis
por: Tsumagari, Koji, et al.
Publicado: (2011)

Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020)

Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Ducharme-Smith, Allison, et al.
Publicado: (2021)

Expression Profiling of FSHD-1 and FSHD-2 Cells during Myogenic Differentiation Evidences Common and Distinctive Gene Dysregulation Patterns
por: Cheli, Stefania, et al.
Publicado: (2011)

Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)
por: Ansseau, Eugénie, et al.
Publicado: (2017)

Type 1 FSHD with 6–10 Repeated Units: Factors Underlying Severity in Index Cases and Disease Penetrance in Their Relatives Attention
por: Salort-Campana, Emmanuelle, et al.
Publicado: (2020)

The International Headache Congress – IHS and EHF joint congress 2021: Virtual. 8-12 September 2021
Publicado: (2021)

The Italian National Registry for FSHD: an enhanced data integration and an analytics framework towards Smart Health Care and Precision Medicine for a rare disease
por: Bettio, Cinzia, et al.
Publicado: (2021)

DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation
por: Banerji, Christopher R S, et al.
Publicado: (2020)

11th ESSD Congress, 2021
Publicado: (2022)

2021 ISV Annual Virtual Congress
por: Cox, Manon
Publicado: (2022)

Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD
por: Wallace, Lindsay M., et al.
Publicado: (2017)

FSHD Myotubes with Different Phenotypes Exhibit Distinct Proteomes
por: Tassin, Alexandra, et al.
Publicado: (2012)

UK Facioscapulohumeral Muscular Dystrophy (FSHD) Patient Registry
por: Wood, Libby, et al.
Publicado: (2014)

Functional domains of the FSHD-associated DUX4 protein
por: Mitsuhashi, Hiroaki, et al.
Publicado: (2018)

FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?
por: Himeda, Charis L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_laonu7soegr3fagk2a55il1fco